Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 126 clinical trials
The Late Presenter Treatment Optimisation Study

HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in Europe

protease
emtricitabine
tenofovir
hiv viral load
oophorectomy
  • 120 views
  • 23 Jan, 2021
  • 29 locations
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

] or emtricitabine/tenofovir alafenamide [FTC/TAF]), in approximately 240 treatment-nave HIV-1 infected adults. In the experimental arms, GSK3640254 will be administered in 3 blinded doses until the

  • 0 views
  • 02 Mar, 2021
  • 35 locations
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia

, Emtricitabine/ Tenofovir acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab, colchicine, dexamethasone, Icatibant, ibuprofen lipidic and

diabetes
pneumonia
hydroxychloroquine
organ failure
coronavirus infection
  • 62 views
  • 18 Feb, 2021
  • 7 locations
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the …

  • 0 views
  • 25 Jan, 2021
  • 16 locations
Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)

To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.

hepatitis b antigen
hepatitis b e antigen
chronic hepatitis
hepatitis
  • 0 views
  • 01 Mar, 2021
Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection

This study will evaluate the safety and virologic effect of an experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01), alone or in combination with antiretroviral therapy (ART), in adults during early acute HIV infection.

antiretroviral agents
hysterectomy
acute hiv infection
hiv-1 infection
antiretroviral therapy
  • 19 views
  • 24 Jan, 2021
  • 5 locations
HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)

This study is a randomized controlled clinical trial of a theoretically based mobile app, HealthMindr, to increase pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) to prevent human immunodeficiency virus (HIV). Participants in the intervention arm will receive access to the HealthMindr app, with information about …

HIV Vaccine
immunodeficiency
hiv test
pre-exposure prophylaxis (prep)
  • 141 views
  • 25 Jan, 2021
  • 3 locations
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study

This is a phase three study to evaluate the safety and efficacy of Pradefovir treatment in chronic hepatitis B patients. Subject will be randomized to Pradefovir group and TDF group at a ratio of 2:1. Treatment duration will be 96w in randomization and followed by 48w in open. The interim …

fumarate
tenofovir
hepatitis
  • 10 views
  • 25 Jan, 2021
  • 1 location
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

DEFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir pharmaco-enhanced with ritonavir and dolutegravir and 2 prespecified NRTIs) with the WHO recommended regimen of 2NRTIs plus a ritonavir-boosted PI (Standard of Care (SOC)). …

antiretroviral agents
antiretroviral
darunavir
ritonavir
antiretroviral therapy
  • 1172 views
  • 28 Feb, 2021
  • 32 locations
Tenofovir to Prevent HBV Reactivation

The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based

hepatitis b core antibody
hepatitis b antigen
tenofovir
hodgkin's disease
hepatitis
  • 16 views
  • 23 Jan, 2021
  • 2 locations